메뉴 건너뛰기




Volumn 58, Issue 5, 2014, Pages 2781-2797

Hepatitis c virus genetic variability and the presence of ns5b resistance-Associated mutations as natural polymorphisms in selected genotypes could affect the response to ns5b inhibitors

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIVIRUS AGENT; NONSTRUCTURAL PROTEIN 5B; NONSTRUCTURAL PROTEIN 5B INHIBITOR; SOFOSBUVIR; UNCLASSIFIED DRUG; URIDINE PHOSPHATE; VIRUS PROTEIN;

EID: 84898645159     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02386-13     Document Type: Article
Times cited : (51)

References (89)
  • 5
    • 84880309916 scopus 로고    scopus 로고
    • Understanding the hepatitis c virus life cycle paves the way for highly effective therapies
    • Scheel TK, Rice CM. 2013. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19:837-849. http://dx.doi.org/10.1038/nm.3248.
    • (2013) Nat. Med. , vol.19 , pp. 837-849
    • Scheel, T.K.1    Rice, C.M.2
  • 6
    • 84874107832 scopus 로고    scopus 로고
    • Perspectives and challenges of interferonfree therapy for chronic hepatitis c
    • Lange CM, Zeuzem S. 2013. Perspectives and challenges of interferonfree therapy for chronic hepatitis C. J. Hepatol. 58:583-592. http://dx.doi.org/10. 1016/j.jhep.2012.10.019.
    • (2013) J. Hepatol. , vol.58 , pp. 583-592
    • Lange, C.M.1    Zeuzem, S.2
  • 7
  • 8
    • 84881314351 scopus 로고    scopus 로고
    • Novel therapies for hepatitisc one pill fits all?
    • Manns MP, von HT. 2013. Novel therapies for hepatitisC-one pill fits all? Nat. Rev. Drug Discov. 12:595-610. http://dx.doi.org/10.1038/nrd4050.
    • (2013) Nat. Rev. Drug Discov. , vol.12 , pp. 595-610
    • Manns, M.P.1    Von, H.T.2
  • 9
    • 0032876683 scopus 로고    scopus 로고
    • Crystal structure of the rna-dependent rna polymerase from hepatitis c virus reveals a fully encircled active site
    • Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. 1999. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6:937-943. http://dx.doi.org/10.1038/13305.
    • (1999) Nat. Struct. Biol. , vol.6 , pp. 937-943
    • Lesburg, C.A.1    Cable, M.B.2    Ferrari, E.3    Hong, Z.4    Mannarino, A.F.5    Weber, P.C.6
  • 10
    • 0025249362 scopus 로고
    • Hepatitis c virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups
    • Miller RH, Purcell RH. 1990. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc. Natl. Acad. Sci. U. S. A. 87:2057-2061. http://dx.doi.org/10.1073/pnas.87.6.2057.
    • (1990) Proc. Natl. Acad. Sci. U. S. A. , vol.87 , pp. 2057-2061
    • Miller, R.H.1    Purcell, R.H.2
  • 11
    • 84876286638 scopus 로고    scopus 로고
    • Hepatitis c virus therapy update 2013
    • Casey LC, Lee WM. 2013. Hepatitis C virus therapy update 2013. Curr. Opin. Gastroenterol. 29:243-249. http://dx.doi.org/10.1097/MOG.0b013e32835ff972.
    • (2013) Curr. Opin. Gastroenterol. , vol.29 , pp. 243-249
    • Casey, L.C.1    Lee, W.M.2
  • 12
    • 84856410313 scopus 로고    scopus 로고
    • Antiviral strategies in hepatitis c virus infection
    • Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. 2012. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56(Suppl 1):S88-S100. http://dx.doi.org/10.1016/S0168-8278(12)60010-5.
    • (2012) J. Hepatol. , vol.56 , Issue.SUPPL. 1
    • Sarrazin, C.1    Hezode, C.2    Zeuzem, S.3    Pawlotsky, J.M.4
  • 13
    • 84876582239 scopus 로고    scopus 로고
    • Treatment of chronic hepatitis c: Current and future
    • Pawlotsky JM. 2013. Treatment of chronic hepatitis C: current and future. Curr. Top. Microbiol. Immunol. 369:321-342. http://dx.doi.org/10.1007/978-3- 642-27340-7-13.
    • (2013) Curr. Top. Microbiol. Immunol. , vol.369 , pp. 321-342
    • Pawlotsky, J.M.1
  • 14
    • 84880934969 scopus 로고    scopus 로고
    • Interferon free regimens for the"difficult-to-treat": Are we there?
    • Londoño MC, Lens S, Forns X. 2013. Interferon free regimens for the "difficult-to-treat": are we there? J. Hepatol. 58:643-645. http://dx.doi.org/10.1016/j.jhep.2013.01.007.
    • (2013) J. Hepatol. , vol.58 , pp. 643-645
    • Londoño, M.C.1    Lens, S.2    Forns, X.3
  • 15
    • 84855246805 scopus 로고    scopus 로고
    • Future treatment of chronic hepatitis c with direct acting antivirals: Is resistance important?
    • Halfon P, Sarrazin C. 2012. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int. 32(Suppl 1):79-87. http://dx.doi.org/10.1111/j.1478-3231.2011.02716.x.
    • (2012) Liver Int , vol.32 , Issue.SUPPL. 1 , pp. 79-87
    • Halfon, P.1    Sarrazin, C.2
  • 16
    • 79955103901 scopus 로고    scopus 로고
    • Treatment failure and resistance with direct-Acting antiviral drugs against hepatitis c virus
    • Pawlotsky JM. 2011. Treatment failure and resistance with direct-Acting antiviral drugs against hepatitis C virus. Hepatology 53:1742-1751. http://dx.doi.org/10.1002/hep.24262.
    • (2011) Hepatology , vol.53 , pp. 1742-1751
    • Pawlotsky, J.M.1
  • 17
    • 84855544169 scopus 로고    scopus 로고
    • An updated analysis of hepatitis c virus genotypes and subtypes based on the complete coding region
    • Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M. 2012. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 32:339-345. http://dx.doi.org/10.1111/j.1478-3231. 2011.02684.x.
    • (2012) Liver Int. , vol.32 , pp. 339-345
    • Nakano, T.1    Lau, G.M.2    Lau, G.M.3    Sugiyama, M.4    Mizokami, M.5
  • 18
    • 61549118827 scopus 로고    scopus 로고
    • Nomenclature and numbering of the hepatitis c virus
    • Kuiken C, Simmonds P. 2009. Nomenclature and numbering of the hepatitis C virus. Methods Mol. Biol. 510:33-53. http://dx.doi.org/10.1007/978-1-59745-394- 3-4.
    • (2009) Methods Mol. Biol. , vol.510 , pp. 33-53
    • Kuiken, C.1    Simmonds, P.2
  • 23
    • 84877580079 scopus 로고    scopus 로고
    • The presence of resistance mutations to protease and polymerase inhibitors in hepatitis c virus sequences from the los alamos databank
    • Alves R, Queiroz AT, Pessoa MG, da Silva EF, Mazo DF, Carrilho FJ, Carvalho-Filho RJ, de Carvalho IM. 2013. The presence of resistance mutations to protease and polymerase inhibitors in hepatitis C virus sequences from the Los Alamos databank. J. Viral Hepat. 20:414-421. http://dx.doi.org/10.1111/jvh. 12051.
    • (2013) J. Viral Hepat. , vol.20 , pp. 414-421
    • Alves, R.1    Queiroz, A.T.2    Pessoa, M.G.3    Da Silva, E.F.4    Mazo, D.F.5    Carrilho, F.J.6    Carvalho-Filho, R.J.7    De Carvalho, I.M.8
  • 25
    • 84858421432 scopus 로고    scopus 로고
    • Drug resistance testing in hepatitis c therapy
    • Poveda E, Soriano V. 2012. Drug resistance testing in hepatitis C therapy. Future Virol. 7:309-321. http://dx.doi.org/10.2217/fvl.12.13.
    • (2012) Future Virol. , vol.7 , pp. 309-321
    • Poveda, E.1    Soriano, V.2
  • 26
    • 84867500308 scopus 로고    scopus 로고
    • Development of global consensus sequence and analysis of highly conserved domains of the hcv ns5b protein
    • Waheed Y, Saeed U, Anjum S, Afzal MS, Ashraf M. 2012. Development of global consensus sequence and analysis of highly conserved domains of the HCV NS5B protein. Hepat. Mon. 12:e6142. http://dx.doi.org/10.5812/hepatmon.6142.
    • (2012) Hepat. Mon. , vol.12
    • Waheed, Y.1    Saeed, U.2    Anjum, S.3    Afzal, M.S.4    Ashraf, M.5
  • 28
    • 79957613599 scopus 로고    scopus 로고
    • Mega5: Molecular evolutionary genetics analysis using maximum likeli-hood, evolutionary distance, and maximum parsimony methods
    • Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likeli-hood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739. http://dx.doi.org/10.1093/molbev/msr121.
    • (2011) Mol. Biol. Evol. , vol.28 , pp. 2731-2739
    • Tamura, K.1    Peterson, D.2    Peterson, N.3    Stecher, G.4    Nei, M.5    Kumar, S.6
  • 30
    • 84877776880 scopus 로고    scopus 로고
    • Beyond telaprevir and boceprevir: Resistance and new agents for hepatitis c virus infection
    • Wyles DL. 2012. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top. Antivir. Med. 20:139-145.
    • (2012) Top. Antivir. Med. , vol.20 , pp. 139-145
    • Wyles, D.L.1
  • 31
    • 84867253952 scopus 로고    scopus 로고
    • Antiviral resistance and directacting antiviral agents for hcv
    • Aloia AL, Locarnini S, Beard MR. 2012. Antiviral resistance and directacting antiviral agents for HCV. Antivir. Ther. 17:1147-1162. http://dx.doi.org/10.3851/IMP2426.
    • (2012) Antivir. Ther. , vol.17 , pp. 1147-1162
    • Aloia, A.L.1    Locarnini, S.2    Beard, M.R.3
  • 33
    • 84861655785 scopus 로고    scopus 로고
    • Resistance to mericitabine, a nucleoside analogue inhibitor of hcv rna-dependent rna polymerase
    • Pawlotsky JM, Najera I, Jacobson I. 2012. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir. Ther. 17:411-423. http://dx.doi.org/10.3851/IMP2088.
    • (2012) Antivir. Ther. , vol.17 , pp. 411-423
    • Pawlotsky, J.M.1    Najera, I.2    Jacobson, I.3
  • 38
    • 84873054024 scopus 로고    scopus 로고
    • Characterization of viral escape in hcv genotype 1-infected patients treated with bms-791325 and pegylated interferon-Alfa and ribavirin
    • McPhee F, Falk P, Fracasso P, Lemm J, Liu M, Kirk M, Hernandez D, Cooney E, Hughes E, Gao M. 2012. Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-Alfa and ribavirin. J. Hepatol. 56(Suppl 2):S473. http://dx.doi.org/10.1016/S0168- 8278(12)61206-9.
    • (2012) J. Hepatol. , vol.56 , Issue.SUPPL. 2
    • McPhee, F.1    Falk, P.2    Fracasso, P.3    Lemm, J.4    Liu, M.5    Kirk, M.6    Hernandez, D.7    Cooney, E.8    Hughes, E.9    Gao, M.10
  • 39
    • 84857186976 scopus 로고    scopus 로고
    • Characterization of resistance to the nonnucleoside ns5b inhibitor filibuvir in hepatitis c virus-infected patients
    • Troke PJ, Lewis M, Simpson P, Gore K, Hammond J, Craig C, Westby M. 2012. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients. Antimicrob. Agents Chemother. 56:1331-1341. http://dx.doi.org/10.1128/AAC.05611-11.
    • (2012) Antimicrob. Agents Chemother. , vol.56 , pp. 1331-1341
    • Troke, P.J.1    Lewis, M.2    Simpson, P.3    Gore, K.4    Hammond, J.5    Craig, C.6    Westby, M.7
  • 41
    • 79952139742 scopus 로고    scopus 로고
    • Resistance profile of abt-333 and relationship to viral load decrease in patients treated in combination with peg-interferon and ribavirin for 28 days
    • Middleton T, He Y, Beyer J, Menon R, Klein CE, Cohen D, Collins C. 2010. Resistance profile of ABT-333 and relationship to viral load decrease in patients treated in combination with peg-interferon and ribavirin for 28 days. J. Hepatol. 52(Suppl 1):S296-S297. http://dx.doi.org/10.1016/S0168-8278(10) 60764-7.
    • (2010) J. Hepatol. , vol.52 , Issue.SUPPL. 1
    • Middleton, T.1    He, Y.2    Beyer, J.3    Menon, R.4    Klein, C.E.5    Cohen, D.6    Collins, C.7
  • 43
    • 75149195123 scopus 로고    scopus 로고
    • In vitro studies demonstrate that combinations of antiviral agents that include hcv polymerase inhibitor ana598 have the potential to overcome viral resistance
    • Thompson PA, Patel RA, Showalter RE, Li C, Appleman JR, Steffy KR. 2008. In vitro studies demonstrate that combinations of antiviral agents that include HCV polymerase inhibitor ANA598 have the potential to overcome viral resistance. Hepatology 48(Suppl):1164A.
    • (2008) Hepatology , vol.48 , Issue.SUPPL.
    • Thompson, P.A.1    Patel, R.A.2    Showalter, R.E.3    Li, C.4    Appleman, J.R.5    Steffy, K.R.6
  • 45
    • 84856440468 scopus 로고    scopus 로고
    • Emergence and persistence of ns5b mutations following combination treatment with tegobuvir (gs-9190) plus standard of care-long-term follow-up from the phase iib study gs-us-1960103
    • Hebner C, Harris J, Oldach D, Miller MD, Mo H. 2011. Emergence and persistence of NS5B mutations following combination treatment with tegobuvir (GS-9190) plus standard of care-long-term follow-up from the phase IIB study GS-US-1960103. J. Hepatol. 54(Suppl 1):S18-S19. http://dx.doi.org/10.1016/S0168- 8278(11)61213-0.
    • (2011) J. Hepatol. , vol.54 , Issue.SUPPL. 1
    • Hebner, C.1    Harris, J.2    Oldach, D.3    Miller, M.D.4    Mo, H.5
  • 53
    • 0344778061 scopus 로고
    • Semianalytical treatment of solvation for molecular mechanics and dynamics
    • Still WC, Tempezyk A, Hawley RC, Hendrickson T. 1990. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 112:6127-6129. http://dx.doi.org/10.1021/ja00172a038.
    • (1990) J. Am. Chem. Soc. , vol.112 , pp. 6127-6129
    • Still, W.C.1    Tempezyk, A.2    Hawley, R.C.3    Hendrickson, T.4
  • 54
    • 20344403522 scopus 로고    scopus 로고
    • Importance of accurate charges in molecular docking: Quantum mechanical/molecular mechanical (qm/mm)approach
    • Cho AE, Guallar V, Berne BJ, Friesner R. 2005. Importance of accurate charges in molecular docking: quantum mechanical/molecular mechanical (QM/MM)approach. J. Comput. Chem. 26:915-931. http://dx.doi.org/10.1002/jcc. 20222.
    • (2005) J. Comput. Chem. , vol.26 , pp. 915-931
    • Cho, A.E.1    Guallar, V.2    Berne, B.J.3    Friesner, R.4
  • 56
    • 84860143899 scopus 로고    scopus 로고
    • The polymorphisms of dna g-quadruplex investigated by docking experiments with telomestatin enantiomers
    • Alcaro S, Costa G, Distinto S, Moraca F, Ortuso F, Parrotta L, Artese A. 2012. The polymorphisms of DNA G-quadruplex investigated by docking experiments with telomestatin enantiomers. Curr. Pharm. Des. 18:1873-1879. http://dx.doi.org/10.2174/138161212799958495.
    • (2012) Curr. Pharm. Des. , vol.18 , pp. 1873-1879
    • Alcaro, S.1    Costa, G.2    Distinto, S.3    Moraca, F.4    Ortuso, F.5    Parrotta, L.6    Artese, A.7
  • 60
    • 78649329129 scopus 로고    scopus 로고
    • Synthesis and biological evaluation of n-substituted-3,5-diphenyl-2- pyrazoline derivatives as cyclooxygenase (cox-2) inhibitors
    • Fioravanti R, Bolasco A, Manna F, Rossi F, Orallo F, Ortuso F, Alcaro S, Cirilli R. 2010. Synthesis and biological evaluation of N-substituted-3,5- diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors. Eur. J. Med. Chem. 45:6135-6138. http://dx.doi.org/10.1016/j.ejmech.2010.10.005.
    • (2010) Eur. J. Med. Chem. , vol.45 , pp. 6135-6138
    • Fioravanti, R.1    Bolasco, A.2    Manna, F.3    Rossi, F.4    Orallo, F.5    Ortuso, F.6    Alcaro, S.7    Cirilli, R.8
  • 62
    • 84873167874 scopus 로고    scopus 로고
    • Rna dependent rna polymerase of hcv: A potential target for the development of antiviral drugs
    • Waheed Y, Bhatti A, Ashraf M. 2013. RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs. Infect. Genet. Evol. 14:247-257. http://dx.doi.org/10.1016/j.meegid.2012.12.004.
    • (2013) Infect. Genet. Evol. , vol.14 , pp. 247-257
    • Waheed, Y.1    Bhatti, A.2    Ashraf, M.3
  • 63
    • 0033571463 scopus 로고    scopus 로고
    • Crystal structure of the rna-dependent rna polymerase of hepatitis c virus
    • Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7:1417-1426. http://dx.doi.org/10.1016/S0969-2126(00)80031-3.
    • (1999) Structure , vol.7 , pp. 1417-1426
    • Ago, H.1    Adachi, T.2    Yoshida, A.3    Yamamoto, M.4    Habuka, N.5    Yatsunami, K.6    Miyano, M.7
  • 65
    • 66149115122 scopus 로고    scopus 로고
    • Crystal structure of a novel dimeric form of ns5a domain i protein from hepatitis c virus
    • Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN. 2009. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83:4395-4403. http://dx.doi.org/10.1128/JVI.02352-08.
    • (2009) J. Virol. , vol.83 , pp. 4395-4403
    • Love, R.A.1    Brodsky, O.2    Hickey, M.J.3    Wells, P.A.4    Cronin, C.N.5
  • 66
    • 0036120573 scopus 로고    scopus 로고
    • Structural analysis of the hepatitis c virus rna polymerase in complex with ribonucleotides
    • Bressanelli S, Tomei L, Rey FA, De Francesco R. 2002. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 76:3482-3492. http://dx.doi.org/10.1128/JVI.76.7.3482-3492.2002.
    • (2002) J. Virol. , vol.76 , pp. 3482-3492
    • Bressanelli, S.1    Tomei, L.2    Rey, F.A.3    De Francesco, R.4
  • 67
    • 0035120615 scopus 로고    scopus 로고
    • Mutational analysis of the structure and functions of hepatitis c virus rna-dependent rna polymerase
    • Qin W, Yamashita T, Shirota Y, Lin Y, Wei W, Murakami S. 2001. Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase. Hepatology 33:728-737. http://dx.doi.org/10.1053/jhep.2001.22765.
    • (2001) Hepatology , vol.33 , pp. 728-737
    • Qin, W.1    Yamashita, T.2    Shirota, Y.3    Lin, Y.4    Wei, W.5    Murakami, S.6
  • 68
    • 84857639534 scopus 로고    scopus 로고
    • Characterization of viral resistance mutations in genotype 1 hcv patients receiving combination therapy with protease inhibitor and a polymerase inhibitor with or without ribavirin
    • Mo H, Hebner C, Han B, Harris A, Bae K, Wong W, Delaney W, Oldach D, Miller MD. 2011. Characterization of viral resistance mutations in genotype 1 HCV patients receiving combination therapy with protease inhibitor and a polymerase inhibitor with or without ribavirin. J. Hepatol. 54(Suppl 1):S484. http://dx.doi.org/10.1016/S0168-8278(11)61227-0.
    • (2011) J. Hepatol. , vol.54 , Issue.SUPPL. 1
    • Mo, H.1    Hebner, C.2    Han, B.3    Harris, A.4    Bae, K.5    Wong, W.6    Delaney, W.7    Oldach, D.8    Miller, M.D.9
  • 71
    • 35748953422 scopus 로고    scopus 로고
    • Advances in the development of new therapeutic agents targeting the ns3-4a serine protease or the ns5b rna-dependent rna polymerase of the hepatitis c virus
    • De Francesco R, Carfi A. 2007. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv. Drug Deliv. Rev. 59:1242-1262. http://dx.doi.org/10.1016/j.addr.2007.04.016.
    • (2007) Adv. Drug Deliv. Rev. , vol.59 , pp. 1242-1262
    • De Francesco, R.1    Carfi, A.2
  • 72
    • 11144231108 scopus 로고    scopus 로고
    • Inhibitors of the hcv ns5b polymerase: New hope for the treatment of hepatitis c infections
    • Beaulieu PL, Tsantrizos YS. 2004. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr. Opin. Investig. Drugs 5:838-850.
    • (2004) Curr. Opin. Investig. Drugs , vol.5 , pp. 838-850
    • Beaulieu, P.L.1    Tsantrizos, Y.S.2
  • 75
    • 84867398802 scopus 로고    scopus 로고
    • The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance
    • Gotte M. 2012. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance. Curr. Opin. Virol. 2:644-650. http://dx.doi.org/10.1016/j.coviro.2012.08.004.
    • (2012) Curr. Opin. Virol. , vol.2 , pp. 644-650
    • Gotte, M.1
  • 82
    • 33845247515 scopus 로고    scopus 로고
    • General catalytic deficiency of hepatitis c virus rna polymerase with an s282t mutation and mutually exclusive resistance towards 2=-modified nucleotide analogues
    • Dutartre H, Bussetta C, Boretto J, Canard B. 2006. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2=-modified nucleotide analogues. Antimicrob. Agents Chemother. 50:4161-4169. http://dx.doi.org/10.1128/AAC.00433- 06.
    • (2006) Antimicrob. Agents Chemother. , vol.50 , pp. 4161-4169
    • Dutartre, H.1    Bussetta, C.2    Boretto, J.3    Canard, B.4
  • 85
    • 84898647381 scopus 로고    scopus 로고
    • Evolution of the hcv viral population from one patient with s282t detected at relapse after sofosbuvir monotherapy
    • Hedskog C, Gontcharova V, Han B, Martin R, Miller MD, Mo H, Svarovskaia ES. 2013. Evolution of the HCV viral population from one patient with S282T detected at relapse after sofosbuvir monotherapy. Antivir. Ther. 18(Suppl 1):A9.
    • (2013) Antivir. Ther. , vol.18 , Issue.SUPPL. 1
    • Hedskog, C.1    Gontcharova, V.2    Han, B.3    Martin, R.4    Miller, M.D.5    Mo, H.6    Svarovskaia, E.S.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.